Calfactant

Summary

Calfactant (CHEMBL1201447) is an approved unknown; indicated across 5 conditions including newborn respiratory distress syndrome and adult acute respiratory distress syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201447
Name	Calfactant
Type	Unknown
Max phase	4

Also known as: Aerofact, Bovine calf lung surfactant, Calfactant, Infasurf, Infasurf preservative free, SF-RI 1, CALFACTANT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
newborn respiratory distress syndrome	4	MONDO:0700081	EFO:1000644
adult acute respiratory distress syndrome	4	MONDO:0100130	MONDO:0100130
lung disorder	4	MONDO:0005275	EFO:0003818
bronchopulmonary dysplasia	3	MONDO:0019091	MONDO:0019091
acute lung injury	2	MONDO:0015796	EFO:0004610

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	5
PHASE3	3
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07350018	PHASE4	RECRUITING	Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome
NCT05960929	PHASE3	RECRUITING	InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT00682500	PHASE3	TERMINATED	Calfactant for Direct Acute Respiratory Distress Syndrome
NCT00999713	PHASE2/PHASE3	COMPLETED	CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
NCT03058666	PHASE3	COMPLETED	Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients
NCT06855043	PHASE1/PHASE2	NOT_YET_RECRUITING	Little Lungs Study
NCT01268215	PHASE2	UNKNOWN	Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.
NCT03969992	PHASE2	COMPLETED	A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
NCT03748173	PHASE1	TERMINATED	Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04
NCT00165074	Not specified	COMPLETED	Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation
NCT00208039	Not specified	COMPLETED	Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
NCT00628134	Not specified	COMPLETED	Self-dispersing Liquids as Aerosol Drug Carriers
NCT02834624	Not specified	COMPLETED	Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
NCT03582930	Not specified	NO_LONGER_AVAILABLE	Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).